Nymox Pharmaceutical Corp. (NYMX) just announced that results from its Phase 2 prostate cancer study demonstrated statistically significant better outcomes at up to 2.8 years for NX-1207 treated patients compared to controls.
Nymox Pharmaceutical has suddenly spiked to the upside on increased volume and is now up 0.64 at $1.63. The stock is challenging the upper end of a 2 1/2 week range.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.